Nanoprobes for sensing of reactive oxygen and reactive nitrogen species
For whole animal in-situ and real-time imaging of inflammation, a dual-color fluorescent nanoprobe is provided for the detection of reactive oxygen and nitrogen species (RONS) in inflammatory microenvironments. The nanoprobes of the disclosure are a RONS-responsive energy transferring nanosystem of a fluorescent conjugated polymer core and a PEG-shell linked with RONS-sensing antennae as a FRET acceptor. These nanoprobes allow in vivo imaging of the entire process of inflammation from the release of local tissue distress signals, to the action of leukocytes and macrophages late in the process of inflammation, through to restitution, allowing in whole-body diagnosis and monitoring of inflammatory diseases.
1. A composition comprising a nanoparticle probe comprising a nanoparticle core comprising a detectable signal-emitting superconducting polymer, a shell attached to the superconducting polymer core by hydrophobic tails and having surface exposed reactive groups, wherein said reactive groups form covalent bonds with a quencher moiety, wherein the nanoparticle probe is an NH 2 -functionalized conjugated polymer nanoparticle (NH 2 -CPN) comprising a core nanoparticle comprising poly[9,9′-dihexyl-2,7-bis(1-cyanovinylene)fluorenylene-alt-co-2,5-bis(N,N′-diphenylamino)-1,4-phenylene] (PCFDP) and the hydrophobic lipid tails of 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG-NH 2 ), whereby the N-[methoxy(poly ethylene glycol)-2000] domain of the DSPE-PEG, and the N-[amino(polyethylene glycol)-2000] domain of the DSPE-PEG-NH 2 comprise the shell substantially surrounding the core nanoparticle; and the quencher is the dye (2-[2-[2-Chloro-3-[2-(1,3-dihydro-1,3,3-trimethyl-2H-indol-2-ylidene)-ethylidene]-1-cyclohexen-1-yl]-ethenyl]-1,3,3-trimethyl-3H-indolium chloride conjugated to the shell.
2. The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.
3. A nanoparticle probe comprising:
(i) a nanoparticle core consisting of the detectable signal-emitting superconducting polymer poly[9,9′-dihexyl-2,7-bis(1-cyanovinylene)fluorenylene-alt-co-2,5-bis(N,N′-diphenylamino)-1,4-phenylene] (PCFDP) and the hydrophobic lipid tails of 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG-NH 2 );
(ii) a shell substantially surrounding the said nanoparticle core, said shell consisting of the N-[methoxy(polyethylene glycol)-2000] domains of the DSPE-PEG and the DSPE-PEG-NH 2 of the core, wherein said N-[methoxy(polyethylene glycol)-2000] domains have reactive groups forming covalent bonds with a quencher moiety; and
(iii) a quencher moiety, wherein said quencher moiety is the dye (2-[2-[2-Chloro-3-[2-(1,3-dihydro-1,3,3-trimethyl-2H-indol-2-ylidene)-ethylidene]-1-cyclohexen-1-yl]-ethenyl]-1,3,3-trimethyl-3H-indolium chloride degradable by a reactive oxygen and nitrogen species (RONS).
4. A method of detecting a site of generation of a reactive oxygen or nitrogen species (RONS) in a human or non-human animal subject comprising the steps of:
(a) administering to a human or non-human subject a pharmaceutically acceptable composition of the nanoparticle probes of claim 1 :
(b) allowing the nanoparticle probes of the administered pharmaceutically acceptable composition to contact a site of inflammation in the subject animal or human;
(c) generating a detectable signal from the detectable signal emitting polymer;
(d) detecting the signal emitted from the detectable signal emitting polymer; and
(e) locating the position of the detectable signal relative to the anatomy of the human or non-human animal subject, thereby identifying a site of generation of a reactive oxygen or nitrogen species (RONS) in the human or non-human animal subject.
5. The method of claim 4 , wherein the site of generation of a reactive oxygen or nitrogen species (RONS) is an inflammation of a tissue of the human or non-human animal or an injured tissue.
6. The method of claim 4 , wherein the pharmaceutically acceptable composition is administered to the human or non-human animal subject topically, intravenously, intraperitoneally, or by injection to a site suspected of being inflamed.
7. The method of claim 4 , wherein the quencher is linked to the detectable signal emitting polymer by a linker cleavable by a reactive oxygen and nitrogen species (RONS).
8. The method of claim 4 , wherein the quencher is degradable by a reactive oxygen and nitrogen species (RONS).
9. The method of claim 4 , wherein the detectable signal emitting polymer is a fluorophore and the signal emitted therefrom is quenched by FRET to the quencher.
10. The method of claim 4 , wherein the detectable signal emitting polymer of the nanoparticle probe is a fluorophore, and wherein the step (c) comprises irradiating the human or non-human animal subject, or a tissue thereof, with an incident radiation inducing fluorescence by the fluorophore.